2017
Mycosis Fungoides and Sezary Syndrome
Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/Oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsHumansImmunologic FactorsMycosis FungoidesSezary SyndromeStem Cell TransplantationT-Lymphocytes, RegulatoryConceptsSkin-directed therapiesSezary syndromeLymph nodesMycosis fungoidesAllogeneic stem cell transplantationSystemic immunomodulatory agentsVisceral organ involvementSingle-agent chemotherapyStem cell transplantationPatch/plaqueHelper T cellsExtent of skinDiffuse erythrodermaBlood involvementOrgan involvementRefractory diseaseVisceral involvementResistant diseaseRare lymphomaCell transplantationImmunomodulatory agentsPlaque diseaseCurative strategiesT cellsDisease
2010
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal Of The American Academy Of Dermatology 2010, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAlkylating AgentsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicCombined Modality TherapyDrug Therapy, CombinationEvidence-Based MedicineHistone Deacetylase InhibitorsHumansImmunologic FactorsMethotrexateMycosis FungoidesQuality of LifeRetinoidsSezary SyndromeSkin NeoplasmsConceptsUnited States Cutaneous Lymphoma ConsortiumSézary syndromeTherapeutic optionsTreatment of SSPreventive services guidelinesCurrent treatment optionsEvidence-based medicineMechanism of actionAdjuvant treatmentMycosis fungoidesPoor prognosisCombination therapyTreatment optionsClinical trialsClinical carePromising treatmentSpecific efficacyStandardized reviewOverall efficacyStandardized criteriaTherapyService guidelinesAdverse effectsImmunopathogenesisTreatment
2007
Mycosis Fungoides: Pathophysiology and Emerging Therapies
Duvic M, Foss FM. Mycosis Fungoides: Pathophysiology and Emerging Therapies. Seminars In Oncology 2007, 34: s21-s28. PMID: 18086343, DOI: 10.1053/j.seminoncol.2007.11.006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesRefractory cutaneous T-cell lymphomaPrimary cutaneous T-cell lymphomaNeoplastic T lymphocytesSafe treatment strategyNon-Hodgkin lymphomaT-cell lymphomaLeukemic variant Sézary syndromeHistone deacetylase inhibitorsOrgan complicationsSystemic regimensCutaneous manifestationsEmerging TherapiesSézary syndromeSkin infiltrationSystemic therapyBiologic agentsCTCL subtypesTreatment strategiesCurrent treatmentT lymphocytesDeacetylase inhibitorsPurine nucleoside phosphorylase inhibitorTherapyCutaneous T-cell lymphoma: Biologic targets for therapy
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCD4 AntigensClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsDrug DesignEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyInterferon-gammaInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsPhotopheresisRecombinant Fusion ProteinsSkin NeoplasmsT-Lymphocyte SubsetsTumor EscapeConceptsCutaneous T-cell lymphomaReceptor-dependent signaling pathwaysEpigenetic changesSignaling pathwaysClonal populationsSkin-homing lymphocytesT-cell lymphomaT cell activationPersistence of tumorHost immune systemCTCL cellsCancer immunosurveillanceImmune cellsLangerhans cellsCytotoxic phenotypeDisease pathogenesisBiologic targetsImmune systemCellsTherapyDiseasePhenotypePathwayImmunosurveillanceActivation
2006
Immunomodulatory Effects of Rexinoids
Foss F. Immunomodulatory Effects of Rexinoids. Seminars In Oncology 2006, 33: 21-25. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.Peer-Reviewed Original ResearchConceptsImmunomodulatory effectsCutaneous T-cell lymphomaReceptor-targeted therapyImproved clinical outcomesT-cell lymphomaPractical clinical approachExtracorporeal photophoresisClinical outcomesDenileukin diftitoxTherapy optionsHematologic malignanciesClinical activityPharmacotherapeutic agentsLymphoid malignanciesClinical approachTumor cellsRexinoidsMalignancyTreatmentDiftitoxLymphomaTherapy